Although some medical devices used in the pediatric population (defined by the US Food and Drug Administration' s [FDA' s] Center for Devices and Radiologic Health as birth through age 21 years) are designed specifically for children, many others are borrowed or jury-rigged from adult applications, or other indications. 1 As an example, stents initially developed for biliary disease have been routinely used to treat stenotic heart vessels in infants and children. 2, 3 Although such practice has often been born of necessity given the relative lack of availability of devices designed for and labeled for pediatric use, it has created a situation where the effectiveness and safety of medical devices used in pediatrics have often gone unstudied, and thus are unknown.
LEGISLATIVE INITIATIVES
Although the Best Pharmaceuticals for Children Act (1997) , the Pediatric Rule in 1998, and the Pediatric Research Equity Act of 2003 tackled challenges in obtaining studies to advance pediatric drug research and aimed to ensure appropriate drug product labeling for children, advancement of medical devices for children was not addressed legislatively until September 2007. This date marked the passage of the Food and Drug Administration Amendments Act, including Title III, the Pediatric Medical Device Safety and Improvement Act (PMDSIA). 4 With the unique regulatory pathways to market available for medical devices and the nature of the medical device industry, PMDSIA necessarily takes a distinct approach from that of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act toward improving the health of children.
The intent of PMDSIA was to address identified shortfalls in the development of medical devices for children. This new law called for an increase in the tracking of pediatric device approvals by the FDA, coordination of the federal response to pediatric device needs, establishmentofapediatricdeviceresearch agenda, strengthening of postmarket surveillance of pediatric devices, and facilitation of pediatric device development.
Specifically, PMDSIA included 2 provisions to stimulate pediatric device development. The first, section 303 of the PMDSIA, eliminated the profit restriction on pediatric devices approved under the Humanitarian Device Exemption approval pathway, which is an alternative device approval pathway that allows medical devices used to treat or diagnose rare diseases or conditions to be approved on the basis of safety and probable benefit. The second provision, section 305 of PMDSIA, authorized appropriations for grants to nonprofit consortia for demonstration projects to promote pediatric device development. 
PEDIATRIC DEVICES: THE CHALLENGES AND RECENT RESPONSES
Unlike the pharmaceutical industry, the medical device industry tends to consist of smaller companies with less financial resources that focus on producing either a single or a few products. Moreover, unlike drugs, the development of medical devices is typically an iterative process, with ongoing evolution and refinement over time with subsequent effect on and changes in patent protection. Once a device makes it on to the market, it may be replaced by a refined design within a relatively short period of time. Thus, incentives to extend periods of marketing exclusivity, which are effective in driving pediatric pharmaceutical studies, may not have similar applicability in the medical devices space.
The need for pediatric medical devices and the challenges of developing and evaluating such devices have been extensively reviewed by the FDA, 1 the Institute of Medicine, 5 the Government Accountability Office (GAO), 6 and others. In brief, small market size, the need for multiple pediatric sizes in certain cases, the expense of trials, barriers to enrollment of children, ethical complexities, and a lack of pediatric device trials infrastructure have been identified as some of the major challenges. In addition, the potential for children to use devices over the long term means that such devices must be especially long-lasting and safe.
Some have suggested that the FDA' s regulatory approach to clearing or approving devices for children makes the development of pediatric devices prohibitive. The regulatory process currently used in evaluating pediatric devices is no different than that for adults. This regulatory process implements the legislative framework established by Congress. That framework sets forth device clearance and approval pathways that do not differ on the basis of whether a device is intended for use in an adult population or a pediatric population. Thus, even though the agency tries to exercise appropriate flexibility in interpreting and implementing the laws that have been established, the agency is bound to work within the established legislative framework. Another limiting factor in pediatric device development is that clinicians with potential device ideas often lack the engineering, business, and regulatory background necessary to develop and commercialize products. Section 305 of the PMDSIA was enacted to assist in correcting this particular deficiency. The FDA' s Office of Orphan Product Development has been charged with implementing this section.
THE VISION: PDC
Section 305 of PMDSIA called for the creation of nonprofit consortia to "facilitate the development, production, and distribution of medical devices" by the following:
Encouraging innovation and connecting qualified individuals who have pediatric device ideas with potential device manufacturers Mentoring and managing pediatric device projects through the development process, which includes identifying projects, designing prototypes, and developing and marketing devices Connecting innovators and physicians with existing US government sources and nonfederal resources Assessing the scientific and medical merit of proposed pediatric device projects Giving assistance, as needed, in areas such as business development, personnel training, prototype development, and postmarket needs* Overall, the PDC serve as providers of scientific and regulatory advice, physical and design resources, and business assistance to individuals attempting to develop medical devices for children. To be successful, a consortium needs to bring together a strong network of experts and organizations, working together to advance pediatric medical devices onto the market.
As mentioned above, the statute calls for the consortia to mentorand manage pediatric devices at various stages of development. Medical device development is often described in terms of stages or phases on the basis of the FDA' s Center for Devices and Radiologic Health' s "Total Product Life Cycle" 7 (Fig 1) . A device starts in the "concept" or idea phase. As a physical model of the device is developed, it enters the "prototype" phase. This phase is generally followed by a "preclinical" phase, which includes bench-top and animal testing. If successful, the "clinical" phase typically follows and consists of testing the device in humans. If clinical testing is successfully completed, a product generally enters the "manufacturing" phase, which refers to the design of production processes that ensure standardization of the device. This phase is followed by the "marketing" phase, where results of study data are submitted to the regulatory agency for clearance or approval, as necessary. Once a device is cleared or approved, a device enters the "commercial use" phase where the device becomes available for purchase on the market. Finally, "obsolescence" occurs as new technologies evolve to replace the existing device. Progression from one stage to the next is not necessarily linear, and there is often fluidity between the various stages of development. One of the primary goals of the PDC is to help devices advance through the various stages of development.
ESTABLISHMENT OF THE PDC
Congress first appropriated federal dollars for the PDC grant program in FY 2009. In that year, the program, administered by the Office of Orphan Products Development, initially funded 3 consortia. Additional funds and an additional grant competition led to the program' s current support of 5 pediatric device consortia in FY 2012. Since its establishment, the PDC grant program has awarded a total of 11 million dollars.
Applicants for funding were judgedonthe organizational capacity of their proposed consortiums to exert a sustained, powerful influence on the field of pediatric device development, as well as on a scientific assessment of potential device projects. The application review involved an assessment of each proposed consortium' s ability to provide appropriate clinical, scientific, business, and regulatory advice. Those who received funding scored best in their abilities to serve as a national platform to advance the development of pediatric medical devices while supporting device projects whose outcomes could have a significant impact on the practice of medicine.
The5currentlyfundedconsortiaareledby, and located in, the following institutions: 
ACCOMPLISHMENTS OF THE PDC
As of July 2012 and according to quarterly updates filed to the FDA, the PDC have assisted in the development of 219 proposed pediatric medical devices, 132 of which are still being actively managed or mentored. Most (83%) of the active device projects supported by the consortia are in the early stages of device development, including the initial concept-generating stage, prototyping (designing models of a device idea), and preclinical (bench and animal testing) stages. Specifics about many of the devices being assisted by the consortia cannot be disclosed for confidentiality and proprietary reasons. However, the GAO' s December 2011 report on pediatric medical devices included information on some of the medical device projects that have been supported by the consortia 6 ( Table 1) . As of the most recent grantee reports available in September 2012, 3 of the 219 proposed devices assisted by the consortia were commercially available. These devices are the Geiger Pyloric Immobilizer (a surgical tool used in pyloromyotomy), the Arbriiz (a computerized asthma-management tool), and the Dynamic Compressor System (an external brace for the treatment of pectus carinitum). The consortia have also advised on the design of several ongoing preclinical and clinical trials for pediatric devices and provided funding guidance for .100 proposed pediatric device projects.
In the first 3 years, .9 million dollars of additional funding for pediatric device research was secured on the basis of advice, partner support, or facilitated interactions between device inventors and potential investors. Thus, the consortia leveraged the government' s 9-million-dollar investment in the program to attract an equal amount of additional funding to advance pediatric device products. In December 2011, the GAO issued a report on pediatric medical device development, including an analysis of the PDC program. The report concluded: "It is too early to determine if the FDAAA provisions authorizing demonstration grants for pediatric device consortia . . . have had a substantial impact on the number of approved pediatric devices." However, the report went on to state: "Programs such as the pediatric device consortia can foster an environment for device innovators to share ideas and advance the development of pediatric medical devices" and "the number of devices that the PDC have supported through the early phase of development and the positive feedback from stakeholders indicate that pediatric devices are being developed."
CONCLUSIONS AND FUTURE DIRECTIONS
In the 3 years since appropriations of federal funding, the PDC grant program has established a national infrastructure for assisting individuals with pediatric device ideas and has advanced pediatric products along the development pathway. An increased awareness about the need for medical devices for children now exists. Funds appropriated to the PDC grant program have been leveraged by the consortia to attract additional funding for pediatric device development projects. Although much has been accomplished, there is still much more work to be done. An RFA (request for applications) for this program will be issued in the spring to announce future funding opportunities for this program. Prospective applicants will be able to access the RFA in the National Institutes of Health Guide for Grants and Contracts. With continued congressional appropriations, it is anticipated that the critical work of developing medical devicesforchildren will continue with assistance from the PDC. 
